Home › Atherosclerosis › Michigan › Farmington Hills
Atherosclerosis clinical trials in Farmington Hills, MI
3 studies for Atherosclerosis are looking for participants at sites in and around Farmington Hills (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
RecruitingPhase 2
- Profound Research LLC at Millenium Cardiology, Farmington Hills
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
RecruitingPhase 3
- Profound Research LLC, Farmington Hills
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
RecruitingPhase 3
- Research Site, Farmington Hills
- Research Site, Southfield · 8 mi away
About Atherosclerosis
Atherosclerosis is hardening and narrowing of the arteries caused by the buildup of a fatty substance called plaque. Learn about the risks and prevention.
More about Atherosclerosis on MedlinePlus
Atherosclerosis trials in other cities
- Boston, MA10 studies
- Houston, TX10 studies
- Washington, DC9 studies
- Arlington, VA8 studies
- Orlando, FL8 studies
- Hialeah, FL8 studies
- Durham, NC7 studies
- Dallas, TX7 studies
- Memphis, TN7 studies
- Las Vegas, NV7 studies
- Miami, FL7 studies
- Minneapolis, MN6 studies
Other studies in Farmington Hills
- Non-Small Cell Lung Cancer13 studies
- Parkinson's Disease13 studies
- Obesity12 studies
- Overweight10 studies
- Breast Cancer10 studies
- Heart Failure9 studies
- Lung Cancer8 studies
- Prostate Cancer8 studies
- Alzheimer's Disease8 studies
- Bladder Cancer6 studies
- Multiple Sclerosis6 studies
- COPD6 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.